April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Treatment of Severe Amblyopia With Atropine: Results From Two Randomized Clinical Trials
Author Affiliations & Notes
  • M. X. Repka
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • R. T. Kraker
    Jaeb Center for Health Research, Tampa, Florida
  • R. W. Beck
    Jaeb Center for Health Research, Tampa, Florida
  • E. Birch
    Retina Foundation of the Southwest, Dallas, Texas
  • S. A. Cotter
    Southern California College of Optometry, Fullerton, California
  • J. M. Holmes
    Ophthalmology, Mayo Clinic, Rochester, Minnesota
  • R. W. Hertle
    Ophthalmology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
  • D. L. Hoover
    Everett and Hurite Ophthalmic Association, Pittsburgh, Pennsylvania
  • D. L. Klimek
    Children's Eye Care & Adult Strabismus Surgery, South Charleston, West Virginia
  • Pediatric Eye Disease Investigator Group
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  M.X. Repka, None; R.T. Kraker, None; R.W. Beck, None; E. Birch, None; S.A. Cotter, None; J.M. Holmes, None; R.W. Hertle, None; D.L. Hoover, None; D.L. Klimek, None.
  • Footnotes
    Support  NIH Grant EY011751
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4753. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. X. Repka, R. T. Kraker, R. W. Beck, E. Birch, S. A. Cotter, J. M. Holmes, R. W. Hertle, D. L. Hoover, D. L. Klimek, Pediatric Eye Disease Investigator Group; Treatment of Severe Amblyopia With Atropine: Results From Two Randomized Clinical Trials. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4753.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effectiveness of weekend atropine for severe amblyopia from strabismus, anisometropia or both combined among children 3 to 12 years of age.

Methods: : We enrolled children into two prospective, randomized multi-center clinical trials of amblyopia therapy. Herein we report the results for severe amblyopia, 20/125 to 20/400. In Trial 1, 60 children 3 to 6 years of age (mean age 4.4 years) were randomized to weekend atropine plus a plano lens with weekend atropine with full spectacle correction for the sound eye. In Trial 2, 40 children 7 to 12 years of age (mean age 9.3 years) were randomized to weekend atropine or two hours of daily patching. The visual acuity outcome was assessed at 18 weeks in Trial 1 and 17 weeks in Trial 2.

Results: : In Trial 1, visual acuity improved by an average of 4.5 lines in the atropine plus correction group (95% confidence interval (CI) 3.2 to 5.8 lines) and 5.1 lines in the atropine plus plano lens group (95% CI 3.7 to 6.4 lines). In Trial 2, visual acuity improved by an average of 1.5 lines in the atropine group (95% CI 0.5 to 2.5 lines) and 1.8 lines in the patching group (95% CI 1.1 to 2.6 lines).

Conclusions: : Atropine can improve visual acuity in children 3 to 12 years of age with severe amblyopia. Improvement may be greater in younger children.

Clinical Trial: : www.clinicaltrials.gov NCT00315328

Keywords: amblyopia • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×